Growing prevalence of cancer has consistently spurred the demand for cancer treatments such as chemotherapy over the past decade. That said, radiation therapy comes with several side effects that are challenging for cancer patients to confront, while they undergo the course of procedure.
While cancer treatment is significantly progressing, rising incidences of side effects are growing as well that are addressed by cancer supportive care products.
Oncology is among the fastest-growing therapeutic areas (TAs) worldwide, and is projected to capture about 26% of pharmaceutical sales by 2022, with 107 novel drug approvals in 2018 alone.
In addition, the domain is highly competitive – 35% of the industry preclinical pipeline lies in oncology, and leading players have a commercial footprint. This investment and interest is partially driven by rapid development cycles.
Technological intervention in cancer supportive care products has enabled to treat various indications following chemotherapy procedure, as well as chemotherapy-induced nausea, vomiting, anemia, and neutropenia.
The global cancer supportive care products market is currently growing at a sound pace and is expected to experience moderate growth over the forecast period, 2020t o 2030.
Biosimilar drugs (or biosimilars), used in management of several disease conditions, account for about 25% of global pharmaceutical industry.
Adoption of biosimilar drugs among patients having cancer has triggered significant advancements in cancer treatments and supportive care.
The USA FDA has approved various biosimilars for treatment of cancer and supportive care management, and the figure is expected to follow a positive trend.
Further, usage of biosimilars is associated with exponential cost-savings. Recent studies stress that biosimilars will result in a reduction of USD 54 Bn in direct expenditure on biologic drugs over 2017 to 2026, or around 3% of overall anticipated biologic spending within the same timeframe, ranging of US $24-150 Bn.
Prominent drivers of cost savings include number and timing of biosimilars in development and marketing, acceptability of usage among prescribers and patients, cost of biosimilar development, changes in global market size, cost-sharing, payer coverage, and other regulatory policies.
Although these figures appear promising, the expected cost savings with usage of biosimilars are projected to remain modest.
Globally, the cost of biosimilars is about 20-30% less compared to that of reference drugs. The cost savings will bank on several factors such as cost of reference drugs, their sales, and degree of competition.
Among the distribution channels, hospital pharmacies are expected to generate greater total return to shareholders (TRS) – over 50% of overall cancer supportive care products market revenue.
About 33% of overall healthcare companies are looking forward to transmuting their whole business model in 2020, with hospitals, the major providers of cancer care, accounting for 66% of them.
Pharmacy is an ever-evolving landscape, as such, hospital pharmacies are striving to keep pace with surging demand for cancer supportive care products and consistent rise in healthcare expenses. With inbound costs of oncology drugs, hospital pharmacies are in a constant juggle to reduce expenses and keep the budget on track.
Hospital pharmacies are monitoring trends on cancer supportive care products that have measurable effect on pharmacy budget in order to ensure maximum savings for hospitals’ pharmaceutical expenses.
While hospital pharmacies continue to capture a bigger slice of cancer supportive care products market value, players are also unlocking new revenue lines in retail pharmacies.
Regionally, North America continues to engage manufacturers of cancer supportive care products over the following decade. Cancer is the major cause of mortality in Canada and the second-leading cause, after cardiovascular diseases (CVD), in the USA
Consequently, governments in the US and Canada are substantially investing in cancer research and development of pharmaceutical drugs, especially erythropoietin stimulating agents, and granulocyte colony stimulating factors.
Moreover, the regulatory authorities have been showing immediacy in approving various cancer supportive care products. The USA has granted approval to around 23 biosimilars by July 2019, of which 14 carry indications for use in oncology.
In a similar vein, Asia Pacific (APAC) is also offering value-capture opportunities for players in of cancer supportive care products market.
Studies reveal that nearly half of the global cancer cases are reported in APAC, and by 2030, the number of individuals fighting cancer is likely to soar by about 35%, with mortality increasing by about 40%.
Biopharmaceutical companies in APAC are beginning to launch APAC-centric clinical therapeutics research. Within oncology domain, major portion of APAC drug development is centered on breast, lung, and colorectal cancers. Carrying an enormous cancer burden, the oncology drug market in China is expected to hit USD 18 Bn by 2023.
Driven by expanding healthcare needs in tandem with supportive government policies. APAC represents tremendous opportunity for cancer supportive care product manufacturers. Countries are implementing steps to set up domestic environments that can leverage local talent and fetch foreign investment.
The cancer supportive care products market is witnessing the penetration of emerging players both at local and international level. The rising level of market competition is making new product launches, innovative applications, and tech-enabled developments a key priority among market players. Some of these include,
Recent medical studies are underway unleashing the potential of cannabis or cannabidiol (CBD) in cancer treatment. With limited number of opportunities for cancer treatment currently, CBD is likely to hold great promise for both patients and scientists in addressing the situation.
Given its cytotoxic, antiemetic, and anti-inflammatory effects, CBD has been garnering huge attention to its possible usage as a potent anti-cancer agent.
While regulatory bodies in the US have prohibited cannabis consumption, several states in the USA, as well as some countries across the globe have legalized cannabis consumption for medical applications.
Two CBD drugs have been approved by the USA Food and Drug Administration (FDA) - nabilone and dronabinol were researched as potent antiemetic medications.
Research and trials are in progress, incorporating swathes of scientists worldwide scrutinizing the potential of CBD for cancer treatment. However, these studies are yet to discover ample concrete scientific evidence to prove the safety and efficacy of CBD oil in treating cancer.
These scientific studies and research have been performed using animals or cancer cells developed in the laboratories. Human beings are more complex compared to animals, as such, results elaborated after the studies might not work as effectively for humans as they did in animal trials.
At present, the loopholes in research studies regarding consumption of CBD oil are creating hindrance for its approval as a potential medication for cancer treatment
Drug Class:
Indication:
Distribution Channel:
Region:
Table 01: Global Market Value By Drug Classes, 2020–2030(US$ Mn)
Table 02: Global Market Value By Disease Indication, 2020–2030(US$ Mn)
Table 03: Global Market Value By Distribution Channel, 2020–2030(US$ Mn)
Table 04: North America Market Value By Drug Classes, 2020–2030(US$ Mn)
Table 05: North America Market Value By Disease Indication, 2020–2030(US$ Mn)
Table 06: North America Market Value By Distribution Channel, 2020–2030(US$ Mn)
Table 07: Latin America Market Value By Drug Classes, 2020–2030(US$ Mn)
Table 08: Latin America Market Value By Disease Indication, 2020–2030(US$ Mn)
Table 09: Latin America Market Value By Distribution Channel, 2020–2030(US$ Mn)
Table 10: Europe Market Value By Drug Classes, 2020–2030(US$ Mn)
Table 11: Europe Market Value By Disease Indication, 2020–2030(US$ Mn)
Table 12: Europe Market Value By Distribution Channel, 2020–2030(US$ Mn)
Table 13: APAC Market Value By Drug Classes, 2020–2030(US$ Mn)
Table 14: APAC Market Value By Disease Indication, 2020–2030(US$ Mn)
Table 15: APAC Market Value By Distribution Channel, 2020–2030(US$ Mn)
Table 16: MEA Market Value By Drug Classes, 2020–2030(US$ Mn)
Table 17: MEA Market Value By Disease Indication, 2020–2030(US$ Mn)
Table 18: MEA Market Value By Distribution Channel, 2020–2030(US$ Mn)
Figure 01: Global Oncology Drug Market Value (US$ Mn) 2020–2030
Figure 02: Global Cancer Supportive Care Drug Market – Scenario Forecast, 2020–2030(US$ Mn)
Figure 03: Global Market Value & Y-o-Y Growth (%), 2020–2030
Figure 04: Global Market Absolute $ Opportunity, 2020–2030
Figure 05: Global Market Y-o-Y Growth Comparison By Drug Classes, 2020–2030
Figure 06: Market Value Share & BPS Analysis By Drug Classes, 2020 & 2030
Figure 07: Global Market Value & Y-o-Y Growth (%) By Nonsteroidal Anti-inflammatory Drugs, 2020–2030
Figure 08: Global Market Absolute $ Opportunity By Nonsteroidal Anti-inflammatory Drugs, 2020–2030
Figure 09: Global Market Value & Y-o-Y Growth (%) By Anti-infective, 2020–2030
Figure 10: Global Market Absolute $ Opportunity By Anti-infective, 2020–2030
Figure 11: Global Market Value & Y-o-Y Growth (%) By Anti-emetics, 2020–2030
Figure 12: Global Market Absolute $ Opportunity By Anti-emetics, 2020–2030
Figure 13: Global Market Value & Y-o-Y Growth (%) Monoclonal Antibodies, 2020–2030
Figure 14: Global Market Absolute $ Opportunity By Monoclonal Antibodies, 2020–2030
Figure 15: Global Market Value & Y-o-Y Growth (%) By Erythropoietin Stimulating Agents, 2020–2030
Figure 16: Global Market Absolute $ Opportunity By Erythropoietin Stimulating Agents, 2020–2030
Figure 17: Global Market Value & Y-o-Y Growth (%) By Opioid Analgesics, 2020–2030
Figure 18: Global Market Absolute $ Opportunity By Opioid Analgesics, 2020–2030
Figure 19: Global Market Value & Y-o-Y Growth (%) By Bisphosphonates, 2020–2030
Figure 20: Global Market Absolute $ Opportunity By Bisphosphonates, 2020–2030
Figure 21: Global Market Value & Y-o-Y Growth (%) By Granulocyte Colony Stimulating Factor, 2020–2030
Figure 22: Global Market Absolute $ Opportunity By Granulocyte Colony Stimulating Factor, 2020–2030
Figure 23: Global Market Attractiveness Analysis By Drug Classes, 2020–2030
Figure 24: Global Market Attractiveness Analysis By Indication, 2020–2030
Figure 25: Global Market Y-o-Y Growth Comparison By Indication, 2020–2030
Figure 26: Market Value Share & BPS Analysis By Indication, 2020 & 2030
Figure 27: Global Market Value & Y-o-Y Growth (%) By Lung Cancer, 2020–2030
Figure 28: Global Market Absolute $ Opportunity By Lung Cancer, 2020–2030
Figure 29: Global Market Value & Y-o-Y Growth (%) By Breast Cancer, 2020–2030
Figure 30: Global Market Absolute $ Opportunity By Breast Cancer, 2020–2030
Figure 31: Global Market Value & Y-o-Y Growth (%) By Prostate Cancer, 2020–2030
Figure 32: Global Market Absolute $ Opportunity By Prostate Cancer, 2020–2030
Figure 33: Global Market Value & Y-o-Y Growth (%) By Liver Cancer, 2020–2030
Figure 34: Global Market Absolute $ Opportunity By Liver Cancer, 2020–2030
Figure 35: Global Market Value & Y-o-Y Growth (%) By Bladder Cancer, 2020–2030
Figure 36: Global Market Absolute $ Opportunity By Bladder Cancer, 2020–2030
Figure 37: Global Market Value & Y-o-Y Growth (%) By Leukemia, 2020–2030
Figure 38: Global Market Absolute $ Opportunity By Leukemia, 2020–2030
Figure 39: Global Market Value & Y-o-Y Growth (%) By Ovarian Cancer, 2020–2030
Figure 40: Global Market Absolute $ Opportunity By Ovarian Cancer, 2020–2030
Figure 41: Global Market Value & Y-o-Y Growth (%) By Melanoma, 2020–2030
Figure 42: Global Market Absolute $ Opportunity By Melanoma, 2020–2030
Figure 43: Global Market Value & Y-o-Y Growth (%) By Other Cancer, 2020–2030
Figure 44: Global Market Absolute $ Opportunity By Other Cancer 2020–2030
Figure 45: Global Market Y-o-Y Growth Comparison By Distribution Channel, 2020–2030
Figure 46: Market Value Share & BPS Analysis By Distribution Channel, 2020 & 2030
Figure 47: Global Market Value & Y-o-Y Growth (%) By Hospital Pharmacies, 2020–2030
Figure 48: Global Market Absolute $ Opportunity By Hospital Pharmacies, 2020–2030
Figure 49: Global Market Value & Y-o-Y Growth (%) By Retail Pharmacies, 2020–2030
Figure 50: Global Market Absolute $ Opportunity By Retail Pharmacies, 2020–2030
Figure 51: Global Market Value & Y-o-Y Growth (%) By Compounding Pharmacies, 2020–2030
Figure 52: Global Market Absolute $ Opportunity By Compounding Pharmacies, 2020–2030
Figure 53: Global Market Attractiveness Analysis By Distribution Channel, 2020–2030
Figure 54: Market Y-o-Y Growth Comparison By Region, 2020–2030
Figure 55: Market Value Share & BPS Analysis By Region, 2020 & 2030
Figure 56: Global Market Value & Y-o-Y Growth (%) for North America Region, 2020–2030
Figure 57: Global Market Absolute $ Opportunity for North America Region, 2020–2030
Figure 58: Global Market Value & Y-o-Y Growth (%) for Latin America Region, 2020–2030
Figure 59: Global Market Absolute $ Opportunity for Latin America Region, 2020–2030
Figure 60: Global Market Value & Y-o-Y Growth (%) for Europe Region, 2020–2030
Figure 61: Global Market Absolute $ Opportunity for Europe Region, 2020–2030
Figure 62: Global Market Value & Y-o-Y Growth (%) for Asia Pacific Region, 2020–2030
Figure 63: Global Market Absolute $ Opportunity for Asia Pacific Region, 2020–2030
Figure 64: Global Market Value & Y-o-Y Growth (%) for Middle East and Africa Region, 2020–2030
Figure 65: Global Market Absolute $ Opportunity for Middle East and Africa Region, 2020–2030
Figure 66: Global Market Attractiveness Analysis By Region, 2020–2030
Figure 67: U.S. Market Value & Y-o-Y Growth (%), 2020–2030
Figure 68: U.S. Market Absolute $ Opportunity, 2020–2030
Figure 69: Canada Market Value & Y-o-Y Growth (%), 2020–2030
Figure 70: Canada Market Absolute $ Opportunity, 2020–2030
Figure 71: North America Market Attractiveness Analysis By Drug Classes, 2020–2030
Figure 72: North America Market Attractiveness Analysis By Indication, 2020–2030
Figure 73: North America Market Attractiveness Analysis By Distribution Channel, 2020–2030
Figure 74: North America Market Attractiveness Analysis By Country, 2020–2030
Figure 75: Argentina Market Value & Y-o-Y Growth (%) , 2020–2030
Figure 76: Argentina Market Absolute $ Opportunity, 2020–2030
Figure 77: Brazil Market Value & Y-o-Y Growth (%), 2020–2030
Figure 78: Brazil Market Absolute $ Opportunity, 2020–2030
Figure 79: Mexico Market Value & Y-o-Y Growth (%), 2020–2030
Figure 80: Mexico Market Absolute $ Opportunity, 2020–2030
Figure 81: Rest Of Latin America Market Value & Y-o-Y Growth (%), 2020–2030
Figure 82: Rest Of Latin America Market Absolute $ Opportunity, 2020–2030
Figure 83: Latin America Market Attractiveness Analysis By Drug Classes, 2020–2030
Figure 84: Latin America Market Attractiveness Analysis By Indication, 2020–2030
Figure 85: Latin America Market Attractiveness Analysis By Distribution Channel, 2020–2030
Figure 86: Latin America Market Attractiveness Analysis By Country, 2020–2030
Figure 87: Germany Market Value & Y-o-Y Growth (%) , 2020–2030
Figure 88: Germany Market Absolute $ Opportunity, 2020–2030
Figure 89: U.K. Market Value & Y-o-Y Growth (%), 2020–2030
Figure 90: U.K. Market Absolute $ Opportunity, 2020–2030
Figure 91: France Market Value & Y-o-Y Growth (%), 2020–2030
Figure 92: France Market Absolute $ Opportunity, 2020–2030
Figure 93: Italy Market Value & Y-o-Y Growth (%), 2020–2030
Figure 94: Italy Market Absolute $ Opportunity, 2020–2030
Figure 95: Spain Market Value & Y-o-Y Growth (%), 2020–2030
Figure 96: Spain Market Absolute $ Opportunity, 2020–2030
Figure 97: Nordic Market Value & Y-o-Y Growth (%), 2020–2030
Figure 98: Nordic Market Absolute $ Opportunity, 2020–2030
Figure 99: Russia Market Value & Y-o-Y Growth (%), 2020–2030
Figure 100: Russia Market Absolute $ Opportunity, 2020–2030
Figure 101: Rest Of Europe Market Value & Y-o-Y Growth (%), 2020–2030
Figure 102: Rest Of Europe Market Absolute $ Opportunity, 2020–2030
Figure 103: Europe Market Attractiveness Analysis By Drug Classes, 2020–2030
Figure 104: Europe Market Attractiveness Analysis By Indication, 2020–2030
Figure 105: Europe Market Attractiveness Analysis By Distribution Channel, 2020–2030
Figure 106: Europe Market Attractiveness Analysis By Country, 2020–2030
Figure 107: Greater China Market Value & Y-o-Y Growth (%), 2020–2030
Figure 108: Greater China Market Absolute $ Opportunity, 2020–2030
Figure 109: India Market Value & Y-o-Y Growth (%), 2020–2030
Figure 110: India Market Absolute $ Opportunity, 2020–2030
Figure 111: Japan Market Value & Y-o-Y Growth (%), 2020–2030
Figure 112: Japan Market Absolute $ Opportunity, 2020–2030
Figure 113: Australia and New Zealand Market Value & Y-o-Y Growth (%), 2020–2030
Figure 114: Australia and New Zealand Market Absolute $ Opportunity, 2020–2030
Figure 115: Rest of APAC Market Value & Y-o-Y Growth (%), 2020–2030
Figure 116: Rest of APAC Market Absolute $ Opportunity, 2020–2030
Figure 117: APAC Market Attractiveness Analysis By Drug Classes, 2020–2030
Figure 118: APAC Market Attractiveness Analysis By Indication, 2020–2030
Figure 119: APAC Market Attractiveness Analysis By Distribution Channel, 2020–2030
Figure 120: APAC Market Attractiveness Analysis By Country, 2020–2030
Figure 121: GCC Market Value & Y-o-Y Growth (%), 2020–2030
Figure 122: GCC America Market Absolute $ Opportunity, 2020–2030
Figure 123: South Africa Market Value & Y-o-Y Growth (%), 2020–2030
Figure 124: South Africa Market Absolute $ Opportunity, 2020–2030
Figure 125: Rest Of MEA Market Value & Y-o-Y Growth (%), 2020–2030
Figure 126: Rest Of MEA Market Absolute $ Opportunity, 2020–2030
Figure 127: MEA Market Attractiveness Analysis By Drug Classes, 2020–2030
Figure 128: MEA Market Attractiveness Analysis By Indication, 2020–2030
Figure 129: MEA Market Attractiveness Analysis By Distribution Channel, 2020–2030
Figure 130: MEA Market Attractiveness Analysis By Country, 2020–2030
The cancer supportive care products market is likely to secure a CAGR of 2.5% through 2032.
The cancer supportive care products market size is estimated to cross USD 26.41 Bn by 2032.
The cancer supportive care products market is likely to record a value of USD 20.63 Bn in 2022.
North America is likely to lead the cancer supportive care products market.
Explore Similar Insights
Cancer Supportive Care Products Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
